Overview

Low-dose Carbon Monoxide (HBI-002) Trial to Evaluate Safety, Tolerability, PK, and Biomarkers in Parkinson's Disease

Status:
NOT_YET_RECRUITING
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
A phase 2a multicenter, randomized, double-blind, placebo-controlled multiple dose study to evaluate the safety, tolerability, pharmacokinetics, of HBI-002, an oral low-dose carbon monoxide (CO) liquid drug product, administered daily over 14 days in subjects with Parkinson's disease (PD).
Phase:
PHASE2
Details
Lead Sponsor:
Hillhurst Biopharmaceuticals, Inc.